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of Screening for Disease” (1968), Wilson and Jungner noted that the 
practice of screening is just as important for securing beneficial 
outcomes and avoiding harms as the formulation of principles. Many 
jurisdictions have since established various kinds of “screening 
governance organizations” to provide oversight of screening practice. 
Yet to date there has been relatively little reflection on the nature and 
organization of screening governance itself, or on how different 
governance arrangements affect the way screening is implemented 
and perceived and the balance of benefits and harms it delivers. 
Methods: An international expert policy workshop convened by 
Sturdy, Miller and Hogarth. 
Results: While effective governance is essential to promote beneficial 
screening practices and avoid attendant harms, screening governance 
organizations face enduring challenges. These challenges are social 
and ethical as much as technical. Evidence-based adjudication of the 
benefits and harms of population screening must take account of 
factors that inform the production and interpretation of evidence, 
including the divergent professional, financial and personal 
commitments of stakeholders. Similarly, when planning and 
overseeing organized screening programs, screening governance 
organizations must persuade or compel multiple stakeholders to work 
together to a common end. Screening governance organizations in 
different jurisdictions vary widely in how they are constituted, how 
they relate to other interested organizations and actors, and what 
powers and authority they wield. Yet we know little about how these 
differences affect the way screening is implemented, and with what 
consequences. 
Conclusions: Systematic research into how screening governance is 
organized in different jurisdictions would facilitate policy learning to 
address enduring challenges. Even without such research, informal 
exchange and sharing of experiences between screening governance 
organizations can deliver invaluable insights into the social as well as 
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Introduction
Just over 50 years ago, the World Health Organization (WHO) 
published a landmark report on the “Principles and Practice 
of Screening for Disease” by James Maxwell Glover Wilson 
and Gunnar Jungner. The report was prompted by the growing 
use of medical tests to identify potential disease in apparently 
healthy individuals, and by a dawning awareness that the 
adoption of such “deceptively easy” tests could cause harm 
without necessarily providing benefit to those tested1. The 
report accordingly sought to clarify the circumstances under 
which screening could be considered appropriate as a means 
of secondary prevention. Over the ensuing half century, the 
practice of screening has continued to evolve, using a growing 
range of technologies to test for more and more conditions, from 
rare genetic disease screening in newborns to cancer screen-
ing in adults. Throughout that period, Wilson and Jungner’s 
report has remained a key point of reference for assessing the 
appropriateness of screening—in particular their ten “principles” 
which specified critical preconditions for pursuing screening 
(Box 1).
Box 1. Wilson and Jungner’s Principles of Screening1
1. The condition sought should be an important health problem.
2. There should be an accepted treatment for patients with 
recognized disease.
3. Facilities for diagnosis and treatment should be available.
4. There should be a recognizable latent or early symptomatic 
stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development 
from latent to declared disease, should be adequately 
understood.
8. There should be an agreed policy on whom to treat as 
patients.
9. The cost of case-finding (including diagnosis and treatment of 
patients diagnosed) should be economically balanced in relation 
to possible expenditure on medical care as a whole.
10. Case-finding should be a continuing process and not a ‘once 
and for all’ project.
As the title of their report makes clear, however, Wilson and 
Jungner appreciated that the practice of screening, includ-
ing how screening is organized and how principles are enacted, 
is just as important for securing beneficial outcomes and 
avoiding harms as the formulation of the principles themselves. 
Accordingly, in the decades since their report was published, 
in a growing number of jurisdictions, a range of governmen-
tal and quasi-governmental organizations have been set up with 
the express aim of exercising oversight of screening practice, 
including reviewing screening interventions, issuing guidance, 
and in some cases establishing organized screening programs 
to oversee quality and coordinate access to screening-related 
services. Within their respective spheres of influence, these 
“screening governance organizations”, as we designate them, 
have worked hard to promote beneficial screening practices 
and avoid attendant harms.
In developing their procedures, screening governance organi-
zations have given considerable thought to the role of clinical 
and epidemiological evidence in assessing the merits of spe-
cific screening interventions. Screening decisions do not depend 
on evidence alone, however. They are also shaped by the 
circumstances under which decision-making takes place, includ-
ing how screening is organized, but also—and crucially—how 
governance itself is organized and practised. This is apparent 
in the diversity of governance organizations that exist in dif-
ferent jurisdictions, in their different powers and remits, and in 
the often markedly different screening regimes they oversee. 
Yet to date, there has been relatively little reflection on the 
nature and organization of screening governance itself, or 
on how different governance arrangements may affect how 
screening is implemented, how it is perceived, and the balance 
of benefits and harms it delivers.
This lack of reflection marks a significant gap in our under-
standing of screening and how it might best be implemented. 
Decisions about whether and how to screen may have political 
as well as practical repercussions. Not least, inter-jurisdictional 
variation in the availability and organization of screening 
can prompt difficult questions about the reasons for such 
variation, potentially undermining public trust in local and 
national arrangements and weakening the legitimacy of screening 
governance organizations. There is consequently a need for a 
closer look at screening governance, including how screening 
governance organizations differ in constitution and the powers 
they exercise, how those differences relate to variation in the 
scope and practice of screening, and how such organizations 
account for their decisions to governments, healthcare providers, 
clinicians and the public.
To address this need, in June 2018, an international group 
of screening experts from nine countries met in London for 
a two-day workshop to commemorate the 50th anniversary 
of Wilson and Jungner’s report, to share and compare 
experiences of screening governance, and to ask: What have 
screening governance organizations achieved to date? What key 
governance challenges remain? And how might collective, 
cross-jurisdictional knowledge-sharing help to address those 
challenges?
     Amendments from Version 1
In Box 2: “Screening governance organizations: some examples”, 
we have added a short description of the Australian Standing 
Committee on Screening, to provide a more adequate summary 
of screening governance arrangements in that country.
To avoid ambiguity, we have replaced all mentions of “the three 
lead authors” with the names “Sturdy, Miller and Hogarth”.
Any further responses from the reviewers can be found at 
the end of the article
REVISED
Page 4 of 17
Wellcome Open Research 2020, 5:158 Last updated: 08 SEP 2020
This paper sets out some key issues that arose in the course 
of the workshop discussions. Rather than attempting to docu-
ment all the data and perspectives presented at the workshop, 
it seeks instead to highlight key areas in which the partici-
pants agreed that governance challenges remained and where 
continuing reflection and development were needed. It consid-
ers achievements and ongoing challenges in three principal 
areas of screening governance: the assessment of the relative 
benefits and harms of screening; the organization of population 
screening programs; and the variations in governance arrange-
ments arising in different contexts. It concludes, as did the work-
shop, that much could be gained through sustained engagement 
across jurisdictions and the creation of further opportunities 
for comparison, reflection and ultimately improvement of 
screening governance.
An expert policy workshop
The workshop was planned and convened by Sturdy, Miller and 
Hogarth, prompted by conversations and questions that had arisen 
in the course of their respective researches into screening gov-
ernance. The remaining workshop participants were recruited 
through personal contacts and snowballing recommendations. 
The aim was not to recruit a “representative” sample of interna-
tional screening experts—if indeed such a thing were possible. 
Rather, we sought to create an opportunity to share, reflect on 
and learn from a diversity of experience regarding the achieve-
ments and challenges of population screening in different 
jurisdictions. To that end, we set out to bring together 
expert actors from a range of different national and regional 
screening governance organizations, plus a number of social 
scientists involved in researching screening policy and prac-
tice, while keeping numbers small enough to permit round-table 
discussion.
The workshop was organized into seven sessions, each devoted 
to a different aspect of screening governance in national and 
cross-national perspectives, and each including short reflec-
tive presentations by three or four participants followed by 
round-table discussion. A final round-table session consid-
ered the findings of the workshop and next steps, including the 
decision to write and publish the present paper.
Based on notes taken at the workshop, Sturdy, Miller and 
Hogarth prepared a first draft of the paper, which was then 
circulated to all participants with a request for corrections, clari-
fication and suggestions for revision. After substantial redraft-
ing, the paper was again circulated to all participants, leading to a 
third and penultimate draft. Following a further round of circu-
lation and minor revisions, the final version was approved by 
all the listed authors. Dr Mary White, Chief of the Epidemiol-
ogy and Applied Research Branch in the US CDC’s Division 
of Cancer Prevention and Control took part in the workshop, 
commented on drafts of this paper and agreed to be acknowl-
edged as a named contributor but not as an author. Dr Alberto 
Gutierrez, a Partner with NDA Partners, who took part in the 
workshop but did not contribute to the preparation of this 
article, agreed to be named in that capacity.
The findings, conclusions, and views expressed in this paper 
are those of the authors individually and collectively. They do 
not necessarily represent the official positions of the organi-
zations they work for. Nor do they claim to represent opinion 
among screening policymakers or practitioners more generally.
Adjudicating the benefits and harms of population 
screening
Emerging at a time of burgeoning enthusiasm for non- 
communicable disease screening2, Wilson and Jungner’s report 
anticipated benefits and highlighted potential harms. Assess-
ing then-current efforts as “at a very early and comparatively 
primitive stage in the systematic detection and treatment of early 
disease”1, the report made a compelling case for systematic, 
evidence-based evaluation of new screening interventions. That 
case has only been strengthened by 50 years of scrutiny, which 
has deepened understanding of the possible sources of harm 
(false positives, false negatives, over-diagnosis) and its many 
manifestations (physical, psychological, financial, social)3–5. As 
Angela Raffle, Anne Mackie and Muir Gray put it: “All 
screening programmes do harm. Some do good as well…”6. 
A central aspect of screening governance is therefore the 
weighing of potential harms against anticipated benefits. To 
that end, Wilson and Jungner emphasized the need for early, 
well-planned research to ensure that “scientific knowledge” 
rather than “folklore” guides screening practice1. Continuing 
awareness of that need has encouraged the growth of clinical 
and epidemiological research capacity and the development of 
an international community of practice, including through pro-
fessional societies and research associations (e.g. International 
Cancer Screening Network, International Agency for Research 
on Cancer Screening Group, International Society for Neonatal 
Screening). In concert with the evidence-based medicine move-
ment, screening governance bodies have done much to advance 
this cause, developing systematic review processes, formulating 
explicit criteria to evaluate screening interventions, articu-
lating evidentiary and methodological standards that accord 
with those criteria (e.g. types of harms, implementation con-
siderations), and tailoring them to the specific populations or 
conditions7–10. Through these activities, and by actively fos-
tering research and methodological refinement more gener-
ally, screening governance organizations have come in many 
cases to stand as exemplary proponents of evidence-based 
medicine.
Enduring challenges
The adoption of clear evaluation criteria and robust evidential 
methods does not obviate the importance of value-based judg-
ments and normative expectations in screening governance6,11. 
For instance, normative expectations inform decisions over 
what criteria are relevant when determining the balance of 
harms and benefits, as is evident from the way screening 
governance bodies have variously augmented or reinterpreted 
Wilson and Jungner’s original ten principles to include values 
such as informed choice and health equity12,13, while value 
judgements also inform how harms and benefits are weighted.
Further evidential challenges arise from the dynamics of 
screening practice itself. Screening governance bodies com-
monly influence evidence production through their decisions 
about what they consider to be adequate evidence (by type, 
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quantity or quality). But decisions taken on the basis of such 
evidence may in turn lead to change in the evidential 
landscape. As Wilson and Jungner realized, implementing a 
screening intervention may severely constrain what kind of 
evidence can be ethically generated thereafter, as that inter-
vention becomes the accepted standard of care1. Moreover, 
once a particular screening test diffuses into practice, both the 
screening technology itself and the practices within which it is 
embedded rarely stand still. Screening bodies are developing 
strategies to enhance their capacity to deal with these 
shifting landscapes, for instance by developing new evaluation 
criteria and evidence review capacity. But in practice, they face 
a fundamental difficulty in adjudicating the balance of benefits 
and harms where screening programs already exist, and where 
testing technology or treatment standards continue to evolve 
relative to the evidence base that provided initial support for the 
screening intervention.
Finally, both the production and the interpretation of evidence 
involve social processes which can complicate the role that 
evidence plays in adjudicating between different policy and 
practice options. Screening governance organizations are not 
the only actors involved in generating and evaluating evidence 
or using it as a basis for decisions about screening 
practice. Practitioner organizations, public and private health-
care organizations and health technology assessment (HTA) 
bodies also evaluate screening interventions and issue guide-
lines and recommendations. The different positions that these 
organizations occupy within the wider social structures of 
screening, as well as the divergent professional and personal 
commitments they represent and the conflicting financial 
interests they may embody, can all lead to differences in 
how evidence is generated and interpreted11,14–16. Providers and 
practitioners responsible for actually delivering screening 
tests and follow-up interventions may be faced with multiple 
guidelines based on different sources of evidence or standards 
of practice, leading to outcomes that may elude the scrutiny 
of screening governance organizations;17 while adoption of 
guidelines depends upon many factors besides simply the 
quality of evidence or the clarity of the guidelines18. Finally, 
clinical and public convictions about the value of screen-
ing may run contrary to screening governance organizations’ 
inclination, on the strength of new or existing evidence, to 
restrict or withdraw access to established screening inter-
ventions—witness for instance the controversy around the 
recommendation of the Swiss Medical Board to cease 
introduction of new mammography screening programs and to 
set a time limit on the ones that exist19. 
As a result of all these factors, screening governance can-
not be reduced simply to rule-governed review of evidence. 
Rather, it must take account of the wider factors that inform the 
production and interpretation of evidence, and indeed what is 
actually considered to be evidence20, as well as the way that 
implications drawn from that evidence are translated into 
recommendations for practice, and the way that those recom-
mendations are implemented in the complex social world of 
medical knowledge and practice. Evidence is necessary but not 
sufficient: screening decisions may be evidence-based, but 
that does not mean that they are unequivocally determined by 
evidence21,22.
Organizing population screening
In looking beyond the principles to the practice of screening, 
Wilson and Jungner appreciated that “the efficient practice of 
screening” may best be secured by coordinating “the whole 
screening operation, beginning with an appeal to the public, 
through screening tests, definitive diagnosis, treatment and 
follow-up, without breakdown in communications at any 
point”. Ideally, such organized initiatives would ensure not 
only that “persons found in need of treatment should be able 
to obtain it”, but that the same services were made available to 
“a whole community”. In light of these stipulations, Wilson and 
Jungner cautioned that it was better to invest in a limited number 
of programs “that are well planned and well executed” than to 
spread resources too thinly by pursuing “every feasible form of 
early disease detection and prevention.” Given inevitable 
funding constraints, moreover, the “benefit and effectiveness 
of the proposed programme” would need to be weighed 
against “other desirable objectives”. To support priority setting, 
Wilson and Jungner proposed an axis of national preparedness 
for screening with, on the low end, poor countries with 
limited organized care that might support “medical aid teams,” 
and on the other end, wealthy countries with highly organized 
care, “where integrated screening operations carried out 
under national arrangements may be expected”. This axis also 
accommodated the phenomenon of wealthy nations with health 
services that were neither integrated nor accessible, and which 
would house “expensive sporadic screening exercises … with poor 
communication and follow-up”1.
Wilson and Jungner contended that organized screening 
operations are more effective than ad hoc or opportunistic 
screening both for maximizing benefits and minimizing harms. 
This contention now is widely accepted and supported by 
evidence. Organized screening programs have other virtues too. 
For instance, unlike ad hoc or opportunistic approaches where 
tests are simply offered to patients seeking clinical attention for 
other purposes, organized screening programs can monitor and 
respond to on-the-ground experience and uptake of screening. 
They can also provide a structure within which to pursue 
informed decision making and monitor and promote equity of 
access and outcome. Consequently, health insurance and care 
systems, both public and private, have increasingly come 
to favor organized screening programs as the best means 
to identify and recruit target populations, ensure relevant 
diagnostic and therapeutic follow-up, and monitor, evaluate 
and quality assure screening pathways23,24. In many cases, such 
programs are organised in concert with or in response to 
guidance from the competent screening governance organiza-
tions, providing screening governance organizations with a 
second critical mechanism by which to shape practice, in 
addition to systematic collection and review of evidence.
Enduring challenges
The implementation of organized screening programs does 
not necessarily mean uniformity of provision, however. Even 
within a single program or jurisdiction, the organization of 
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screening may not be consistent or comprehensive. Such 
internal variation impedes clarity about the pre-conditions 
of good outcomes. It also complicates efforts to compare 
performance and share insights across programs and jurisdic-
tions. Indeed, what is meant by “organized” screening may itself 
vary markedly across jurisdictions, even for the same condition: 
programs in one jurisdiction may be organized only insofar as 
they involve systematic cohort notification or data registration, 
while those in another may organize the full screening 
pathway including failsafe mechanisms and quality assurance25. 
Consequently, organized screening programs vary widely in the 
extent and nature of the services they provide.
This variation is not due solely to differences in “national 
preparedness”—the spectrum of organizational capacities 
and capabilities of national healthcare systems that Wilson 
and Jungner pointed to. Another key factor is the uneven 
organizational capacity and authority that screening govern-
ance organizations possess. Human and financial resources 
and sound management are needed to coordinate, quality 
assure and evaluate a screening pathway. Availability of data 
infrastructure, in particular, is often crucial if population-based 
screening programs are to be implemented, monitored and 
evaluated effectively26. But screening governance organizations 
vary in their ability to mobilize such resources. They also 
differ in their powers to engage with health insurance and 
care systems that execute some or all of the steps in the full 
screening pathway. Screening governance organizations thus 
exist on a spectrum defined by their capacity to organize and 
coordinate programs. At one extreme are organizations that 
possess little more than a structured review function, with 
only a limited role in coordinating screening pathways or 
even in specifying how they should perform. At the other are 
organizations with the resources to mount pilot programs 
and conduct research including long term follow-up, and 
with the authority to guide and quality assure the conduct of 
screening and treatment by health care professionals and 
provider organizations. Even in the latter case, however, 
screening governance organizations are acutely dependent on 
the state of development of the relevant healthcare services and 
functions and on the extent to which diagnostic and treatment 
services are integrated, available and accessible. This poses 
a major constraint on screening governance organizations’ 
ability to design and direct effective programs. Under such 
circumstances, questions of equity and ethics may profoundly 
influence decisions about whether or not to establish screening 
programs in specific contexts27. 
Screening governance organizations are not typically in a posi-
tion to determine how much resource or authority they possess. 
Indeed, what screening “is” in any one country reflects prag-
matic realities in the allocation of responsibility for different 
practices. Such jurisdictional realities may produce expansive 
definitions of screening. The UK National Screening Com-
mittee, for example, brings a wide range of screening ini-
tiatives into one common programmatic framework, even as 
each screening program is executed independently across four 
distinct health systems. Elsewhere, however, screening govern-
ance organisations may have to work with more limited defi-
nitions of screening. In Australia, Italy and the Netherlands, 
for example, national screening programs forge a common 
approach across distinct states or regions for an intentionally 
narrow set of conditions, while other screening services are 
organised separately from these national programs, often on a 
regional basis.
Variation in the nature of organized screening programs is fur-
ther complicated by the occurrence of opportunistic or ad hoc 
screening. Opportunistic screening may exist in the absence 
of organized effort, as is the case for PSA-based prostate can-
cer screening, which has been endorsed by few screening 
governance organizations. Alternatively, opportunistic or ad hoc 
screening may exist alongside organized screening programs, 
as is sometimes the case for cervical or breast cancer screening, 
especially where screening is pursued outside recommended 
guidelines (e.g. over or under recommended age limits, 
or at greater frequency). These overlaps may have serious 
implications for extant or potential organized screening pro-
grams. Even where screening governance organizations exer-
cise strict control over organized programs, they are generally 
unable to control the ad hoc or opportunistic screening that may 
exist in parallel, nor can they avert the harms that are likely to 
occur where such screening occurs against express recommen-
dations. Individuals who pursue opportunistic screening may 
not be able to secure timely access to the follow-on testing and 
treatment that an organized program can assure; or they may 
find themselves referred for follow-up in circumstances where it 
would not normally be justified; or they may be exposed to 
other unwarranted harms or costs. This may in turn have impli-
cations for screening governance organizations. In the absence 
of systematic data about the conduct and outcomes of com-
peting or overlapping ad hoc and opportunistic screening, 
screening governance organizations’ ability to evaluate, quality 
assure and where necessary modify organized screening 
programs may be confounded and compromised25. 
Decisions about screening programs, then, are not necessar-
ily just about whether or not to screen. They may be also about 
whether the initiation or termination of an organized approach 
will lead to improvements of one kind or another—be it in 
equality of access, or quality of testing and decision-making, or 
achieving a better balance of benefits and harms. Here too, 
value-based judgments and normative expectations are 
unavoidable. Decisions about where to focus organized screen-
ing effort and how to define the scope of screening programs do 
not simply follow from what is technically possible. Difficult 
trade-offs may be necessary, for example between the opportu-
nity to increase access by under-served populations to existing 
screening interventions and the opportunity to establish new 
screening programs. Or circumstances may warrant the pursuit 
of less-than-optimal solutions: an organized and quality-
assured program may increase benefit and reduce harm relative 
to an ad hoc or opportunistic program, for instance, even if 
the balance between benefit and harm would not justify the 
intervention in the first instance.
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These organizational and institutional factors add a further 
dimension to the complexities and uncertainties we have already 
identified in relation to evidence review and evidence-based 
decision-making. As in the evaluation and weighting of evi-
dence, judgements about how to organize screening programs 
have a strongly social dimension, colored by the play of profes-
sional and personal commitments and institutional and financial 
interests. And this too has implications for the work of screen-
ing governance organizations. In planning and overseeing organ-
ized screening programs, screening governance organizations 
do not only deal with evidence; they also need to engage with 
and take account of the concerns and interests of multiple stake-
holders, from patients to practitioners to healthcare providers. 
Ultimately, the effectiveness of screening programs—their abil-
ity to deliver benefits while minimizing harms to individuals 
and populations—depends on how well these stakeholders 
can be encouraged or compelled to work together to a common 
end.
Organizing screening governance
The challenge confronting screening governance organizations 
is thus not simply a technical one of assessing evidence and 
designing organized programs. It is also a question of how 
to coordinate social action, often under conditions of some 
uncertainty. How screening governance organizations achieve 
this is a vital aspect of the work of screening governance 
itself. And in this respect, much may depend on just how 
screening governance bodies are constituted, how they are 
situated in relation to other interested organizations and actors, 
what powers are vested in them, and what authority they 
wield.
Unsurprisingly, given the diverse political and healthcare 
settings in which they have emerged, screening governance 
organizations vary widely (see Box 2). Some are designated 
agents of government while others are independent committees 
of experts. Some are national with broad clinical scope; others 
are regional and focused on specific clinical areas. Some 
issue recommendations (variously to clinicians, health insur-
ance and healthcare organizations, and government bodies) 
while others have formal authority, including the power to 
require reimbursement by insurers or action by health systems. 
To date, little effort has been made to understand how the 
social organization of screening governance affects the way 
screening itself is implemented, and with what consequences. 
However, we can identify a number of issues around which 
challenges may arise.
Enduring challenges
A key challenge facing screening governance organizations is 
how to negotiate the often conflicting interests and values of 
the different stakeholders involved in delivering the various 
elements of a screening program. Just whose voices get heard 
can significantly affect screening decisions, for instance over 
what conditions to include in newborn screening programs28. 
Certain stakeholders may enjoy formal representation within 
screening governance organizations. More generally, screening 
governance organizations may be in a position to convene 
discussions with other organizations with overlapping roles 
  Box �.  Screening governance organizations: some examples
•     The Netherlands: Health Council of the Netherlands (est. 
1902) https://www.healthcouncil.nl/about-us/history
o     National government advisory body with very 
broad clinical scope
o     Advises Ministers and Parliament on matters of 
public health including population screening
o     Since 1997 charged with assessing applications 
for government licenses to undertake population 
screening
•     The Netherlands: National Institute for Public Health 
and the Environment (1909) https://www.rivm.nl/en/
about-rivm/rivm
o     National government agency with broad public 
health scope
o     Advises the Minister on the introduction and 
modification of screening programs
o     Designs, directs and coordinates national 
screening programs
•     Canada: Task Force on Preventive Health Care 
(formerly Canadian Task Force on the Periodic Health 
Examination, est. 1976) https://canadiantaskforce.
ca/about/history/
o     National government agency with broad clinical 
scope
o    Issues recommendations to clinicians
•     USA: Preventive Services Task Force (1984) https://
uspreventiveservicestaskforce.org/uspstf/procedure-
manual-section-1
o    Independent committee of experts supported by 
government agency with broad clinical scope
o    High grade recommendations necessitate coverage 
by commercial insurers and states through 
Medicare and Medicaid
•     USA: Advisory Committee on Heritable Disorders in 
Newborns and Children (2003) https://www.hrsa.gov/
sites/default/files/hrsa/advisory-committees/heritable-
disorders/about/ACHDNC-Discretionary-Charter.pdf
o     Statutory committee of experts appointed by the 
US Secretary of Health and Human Services
o     Advises government on screening for heritable 
disorders in newborns and children
•     Ontario, Canada: Cancer Care Ontario (1997) https://
www.cancercareontario.ca/en/cancer-care-ontario/
about-us
o     Provincial government agency with scope for 
cancer control
o     Issues evidence-based recommendations to 
government
o     Plans, implements and operates Ontario’s 
organized cancer screening programs
•     Ontario, Canada: Newborn Screening Ontario (2006) 
https://www.newbornscreening.on.ca/en/about-us
o     Provincial non-governmental agency with scope for 
newborn screening
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related to screening activities—for instance the health 
insurance and healthcare organizations that offer ad hoc and 
opportunistic screening tests, or the professional associations 
whose guidelines on screening may conflict with those issued 
by screening governance organizations. As such, screening 
governance organizations may play a pivotal role by facilitating 
participation among the various scientists, clinicians and other 
healthcare providers whose research and care standards are 
critical to screening-relevant care, and whose decisions and 
practices can increase benefits or lead to harm.
Yet little has been done to examine how different screening 
organizations engage with scientists and clinicians, or how 
they involve them in evidence review and recommendation 
processes or the design and delivery of organized screening 
programs. We have only very patchy knowledge about which 
stakeholders are considered by different screening organiza-
tions to have a legitimate “stake” in deliberations over evidence 
or the design and delivery of organized programs, or about the 
processes they use to accommodate or respond to stakeholders’ 
views. Nor do we have any systematic insight into what types 
or processes of engagement are most effective at securing 
coordinated action around screening, under what circumstances, 
and with what outcomes or impacts. In principle, many screening 
governance bodies have the organizational depth and stay-
ing power needed to develop and support processes of engage-
ment and deliberation that will potentially lead to significant 
improvements in the effectiveness of screening programs. In 
practice, however, we lack any overview of what different 
screening organizations actually do in this regard, let alone any 
insight into what works.
Questions of engagement do not extend solely to profession-
als and healthcare providers. They also potentially extend to the 
individuals and populations who undergo screening, and who 
stand to experience both the benefits and the harms that screen-
ing may deliver. These people, as much as the professionals, 
determine the legitimacy of screening interventions, be it by 
bringing political pressure to bear on the relevant authorities or 
simply by consenting or declining to participate in screening. 
Screening governance organizations are often active in 
communicating their conclusions and rationales widely and for 
diverse publics29, and there is evidence that active engagement 
may have a significant impact on public attitudes towards 
screening30. They may also have the capacity to provide 
opportunities for public input, for example through public 
membership of review committees, or stakeholder input 
on draft recommendations. This too raises questions about 
exactly whose views should be taken into account: just those 
individuals identified as having a positive screening test 
result, or all members of a target population, or entire national 
populations? Public attitudes regarding the desirability of 
screening may depart markedly from expert evaluations based 
on evidence of harms and benefits, and may differ between 
those affected and those unaffected by particular diseases31,32. 
This raises profound ethical questions about who should be 
involved in screening policy decisions, and what methods 
should be adopted to elicit or inform their views. As yet, 
however, we have no systematic overview of what different 
screening bodies do to engage participants or publics, or to 
what effect. Given growing expectations of patient involvement 
in the planning and delivery of healthcare services, however, 
much could be gained from more concerted reflection on what 
public and patient engagement can contribute to screening 
governance.
Conclusions
Wilson and Jungner’s 1968 report remains a critical touch-
stone in efforts to adjudicate and balance the benefits and harms 
of population screening. Half a century on, their principles and 
their attention to practices have informed the emergence of a 
range of governance organizations employing sophisticated 
o     Advisory Council established in 2010 reviews 
program quality and issues recommendations to 
government
•     UK: National Screening Committee (1996) https://www.
gov.uk/government/groups/uk-national-screening-
committee-uk-nsc
o     National government agency with broad clinical 
scope
o     Advises on action by the health systems of the UK’s 
four countries.
•     Australia: Medical Services Advisory Committee (1998) 
http://www.msac.gov.au/
o     Independent non-statutory committee established 
by the Minister for Health, with broad clinical remit
o     Appraises new medical services proposed for 
public funding, including national screening 
services




o     Advisory body to national, state and territory 
governments on national cancer screening 
programs and issues, with an emerging advisory 
role in relation to newborn screening
•     Italy: Osservatorio Nazionale Screening (2001) https://
www.osservatorionazionalescreening.it/content/chi-
siamo
o     Independent Agency mandated by National and 
Regional Governments
o     Monitors screening programs nationwide, and 
makes recommendations on new screening 
programs




o     Advisory Group to Ministry of Health (who advises 
government) with broad clinical scope
o     Issues recommendations to the Ministry of Health 
for national population screening programs
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governance mechanisms, including structured evidence review 
processes to determine whether and how to screen, and pro-
grammatic efforts to maximize benefits and minimize harms. 
At a meeting of international screening experts convened 
in the summer of 2018 to reflect on Wilson and Jungner’s 
contribution to the governance of screening, participants 
highlighted that organized oversight and accountability for 
population screening remains crucial. Only through coordinated 
governance procedures can recommendations about screening 
invoke clear criteria, robust systems of evidence review and 
deliberation, and transparent processes of communication and 
public engagement. Such procedures are equally important to 
ensure that screening practices address defined populations, 
provide integrated screening and care pathways, possess robust 
data capacity, and ensure detailed quality assurance and long-term 
follow up.
At the same time, the workshop participants expressed a desire 
for more sustained reflection on how screening governance 
works in different jurisdictions, and how the organization and 
implementation of governance procedures impacts on screening 
recommendations, programs, and ultimately outcomes. There 
is a perceived need for greater awareness and understanding 
of these critical issues, including how screening governance 
bodies are constituted, what powers they possess, how they 
exercise those powers, how they engage with stakeholders 
including healthcare providers and publics, and how all these 
factors affect decision-making processes and the outcomes 
of those decisions.
That is not to suggest that there should be greater standardiza-
tion or homogeneity of screening governance arrangements 
across jurisdictions. The social, political and economic circum-
stances under which screening is enacted vary enormously, 
and governance arrangements need to remain attuned to local 
circumstances. But learning across borders can still be valu-
able. One way to pursue such learning would be through 
research that characterizes and compares screening organizations 
and governance arrangements across clinical conditions and 
across countries. But even in the absence of such research, 
enhanced opportunities and incentives for informal exchange 
and engagement between different screening governance organi-
sations, including sharing experiences and insights into best 
practices, could be beneficial. Indeed, in such complex arenas 
of policy and practice, holistic, experience-based apprehension 
of how different organizations have adapted to deal with the 
contingent circumstances under which they operate may be a 
more fruitful means of adaptive policy learning than formalised 
comparison33,34. Academic research can do much to facilitate 
policy learning. But even in the absence of such research, infor-
mal exchange and sharing of experiences between screening 
governance organizations and cognate expert bodies has the 
potential to deliver invaluable insights into the social as well as 
the technical aspects of governance. Those involved in the 
work of screening governance may learn much from observ-
ing how sister organizations in other jurisdictions exercise the 
authority and powers vested in them, how this relates to vari-
ation in the scope and practice of screening, how they engage 
the interests of practitioners and publics, and how effective 
governance can ensure the legitimacy and public acceptability 
on which screening ultimately depends.
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This Open Letter is based on a Workshop organised in 2018 to commemorate 50 years of the 
Wilson and Jungner criteria. 
  
I agree with Professor Cornel that there is an over-emphasis on cancer screening and too little 
discussion on genetic screening. I feel there is insufficient discussion of how the original 1968 
Wilson and Jungner criteria do not work for genetic screening as has been discussed by others: 
Reference 12 - Andermann, A., Blancquaert, I., Beauchamp, S. & Dery, V. Revisiting Wilson and 
Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health 
Organ 86, 317-9 (2008). 
But also:
Grosse, S.D. et al. Population screening for genetic disorders in the 21st century: evidence, 
economics, and ethics. Public health genomics 13, 106-15 (2010).
○
Andermann et al. (20111). ○
 
The insistence in Wilson and Jungner 1968 on a treatment being available means that genetic 
screening does not fit the criteria. For example, strict adherence to the 1968 Wilson and Jungner 
criteria has been used to block newborn screening for Duchenne muscular dystrophy, because 
there was no cure for Duchenne muscular dystrophy. This has led to who knows how many 
second, third or more affected boys being born to couples who might have wanted to avoid 
having more than one affected son. 
 
Similarly, there is insufficient discussion that the 1968 Wilson and Jungner criteria do not fit with 
current public opinion or government thinking on reproductive carrier screening. 
  
Reproductive carrier screening does not fit with 1968 Wilson and Jungner in that again there is no 
treatment for many of the diseases now screened for. The benefit is not to a patient but to 
prospective parents. In relation to public opinion, from my Group’s work, we know that two-thirds 
of Western Australians wish access to reproductive carrier screening, while only 10% do not want 
to access it (Ong et al., 20182). 
  
1968 Wilson and Jungner does not fit with Government thinking in Israel, which is running a 
nationwide panethnic carrier screening program (Zlotogora et al., 20163), or Australia, where the 
Federal Health Minister has called for reproductive carrier screening to be made available in the 
future free to all Australians who want to use it (Delatycki et al., 20194 and Casella, 20205). 
  
I just wish that articles about Wilson and Jungner criteria, especially articles on governance of 
screening, would strongly acknowledge that strict adherence to 1968 Wilson and Jungner is no 
longer viable, and that every “screening governance organization” needs to use modified Wilson 
and Jungner criteria in 2020. 
  
This Open Letter however is based on a specific workshop, so if these things were not discussed at 
the Workshop, then perhaps they cannot be included in the Open Letter. It may then be up to 
others to publish counter arguments at a later date.  
  
In Australia, as well as the Medical Services Advisory Committee (MSAC) (http://www.msac.gov.au/
), which advises the Federal Government on which items the Federal Government should fund for 
the population, there is the Standing Committee on Screening: (
http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/standing-
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committee-on-screening) (SCOS). The SCOS advises the Australian Health Ministers Advisory 
Council (AHMAC) on which conditions should be screened for. AHMAC includes the Federal and 
State Health Ministers. Newborn screening in Australia is not funded by the Federal Government, 
but by the Health Departments of the individual States and Territories. Newborn screening is 
therefore not under the Federal Health Department’s jurisdiction, and MSAC is therefore irrelevant 
to newborn screening in Australia. 
  
Minor comment, under “Methods” and “An expert policy workshop”, which are the three lead 
authors? The first three authors or the last three authors or a mixture? Would it be clearer to 
simply give their names? 
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I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 10 Aug 2020
Steve Sturdy, University of Edinburgh, Edinburgh, UK 
Like Prof Cornel (reviewer 1), Prof Laing notes that more workshop participants came from 
the field of cancer screening than from genetic screening. As both reviewers observe, 
different kinds of conditions, and different kinds of tests, entail different assessments of 
potential harms and benefits; indeed, every proposed screening intervention needs to be 
evaluated on its particular merits. However, our aim in the workshop and in this open letter 
was to step back from specifics, and to explore issues common to the experience of all the 
participants, which we believe need to be taken into account when considering governance 
arrangements for screening interventions in general. Besides experts from cancer 
screening and from organisations with a comprehensive purview of all kinds of population 
screening, the workshop included several participants with particular expertise in screening 
for genetic disorders. All participants contributed fully to the proceedings and to the 
drafting and finalization of the open letter, and all approved the views expressed. We are 
therefore confident that we have succeeded in our aim of identifying issues of relevance to 
the governance of all forms of population screening modalities across a range of 
jurisdictions. 
 
Regarding Prof Laing’s comment that “strict adherence to 1968 Wilson and Jungner is no 
longer viable”: We should stress that our article does not advocate strict adherence to the 
precise 1968 principles. On the contrary, we point out the complexities and uncertainties 
inherent in weighing the harms and benefits of a growing diversity of screening 
interventions, and the ways that the 1968 principles have therefore been variously 
reinterpreted and augmented. Our intention was to invoke the spirit as much as the letter 
of the Wilson and Jungner reflections on screening governance, and to highlight in 
particular their often-neglected observation that practice is as important as principles in 
ensuring that screening delivers a positive balance of benefit over harm. Space did not 
permit us to pursue this insight down to the level of individual screening interventions. 
Instead, we sought to draw general reflections on how screening governance might best be 
arranged in order to ensure that all kinds of screening interventions, including genetic as 
well as cancer screening, deliver appropriate benefits to the populations they are designed 
to serve. There will be far more to say about just what this might entail for particular 
interventions and particular circumstances – and we are delighted that our reviewers have 
already begun to pursue that conversation. 
 
On a point of accuracy, Prof Laing noted a deficiency in our summary, in Box 2, of Australian 
screening governance arrangements. We have now amended that entry with the addition of 
the Standing Committee on Screening. 
 
On a specific textual point, Prof Laing helpfully notes that it is unclear whom we refer to 
when we talk of the “lead authors” of this open letter. We have now replaced that phrase 
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The paper presents a report based a workshop organized in 2018. It provides reflections on the 
governance of population screening programmes, which indeed is very topical and much needed. 
Governance of screening in many countries faces challenges of a changing landscape in terms of 
technical possibilities for testing and treatments becoming available, while resources are limited. 
 
The participants were chosen from personal contacts and snowballing. This seems to have led to 
an overrepresentation of the Cancer Screening field, as well as Anglophone countries, and an 
underrepresentation of international umbrella-organizations and “genomic” screening (See 
Andermann 2008). Reproductive screening and neonatal screening may raise different issues in 
terms of evidence and ethics.  
 
As a separate issue, “governance” may be considered a multi-step procedure where some 
stakeholders are involved in the (scientific) weighing of the evidence before a decision is made 
whether or not to start a screening, while other stakeholders are involved in the decision making 
on ethical and economical aspects (Ministry of Health, Parliament). Is “governance organization” a 
correct framing, or should rather the different steps in governance be studied in future analyses? 
Is the governance different for considering expansion of screening vs. responsible 
implementation of current screening programs?
 
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
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expertise to confirm that it is of an acceptable scientific standard.
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Steve Sturdy, University of Edinburgh, Edinburgh, UK 
Prof Cornel rightly observes that our method of recruiting participants meant that English-
speaking countries were better represented than others. In consequence, we acknowledge 
that the views shared in the workshop and in the open letter focused mainly — though not 
exclusively — on the experiences of Western/English speaking countries. We hope that this 
open letter will help to stimulate further conversations covering a wider range of 
communities and jurisdictions. 
 
Prof Laing (reviewer 2) raises the same question as Prof Cornel regarding differences 
between cancer screening and genomic, antenatal and newborn screening. We therefore 
discuss this question in our response to Prof Laing’s comments. 
 
On the question of governance as a multi-step procedure: a distinction can be drawn 
between scientific assessment of evidence on one hand and ethical, economic and social 
aspects of decision making on the other. However, one of the key points arising from our 
deliberations was that in practice, collection and evaluation of evidence regarding the 
establishment and expansion of screening unavoidably involves ethical, economic and/or 
social considerations about responsible implementation, just as much as does the 
assessment of existing screening programs. That is not to say that there is no value in 
organising screening governance in a multi-step fashion, to reflect the different issues that 
may be involved in different kinds of decision making. But any decision to do so will need to 
be taken on pragmatic grounds, considering what is practical and appropriate under the 
prevailing circumstances, and not on the assumption that some aspects of governance are 
purely technical or scientific, while others are ethical or social.  
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